Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.8752W HIGH $27.20
Volume
715.95 K
Value Traded
7.60 M
Short % Float
7.85%
Days to Cover
4.3
+16.69%Week
-5.89%1 Month
+25.78%3 Month
+14.99%6 Month
-10.21%5 Year
-10.21%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.13 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
1.88 B
Total Shares
69.39 M
Float Shares
35.83 M
Insiders
48.36%
Institutions
24.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ALMR Catalyst Timeline
Dated clinical, regulatory and corporate events for Alamar Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alamar Biosciences, Inc.
5Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How ALMR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 45%
Small Cap(rank 296 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ATTO-1310 Small moleculeNCT07833306 | Chronic Pruritus of Unknown Origin | Phase 2 | NOT YET_RECRUITING | 300 | Oct 30, 2028 | ||||||
| ATTO-1091 Small moleculeNCT07819799 | Ulcerative Colitis (UC) | Phase 1 | NOT YET_RECRUITING | 96 | Jul 15, 2028 | ||||||
| ATTO-3712 Small moleculeCompletedNCT07205081 | Atopic Dermatitis (AD) | Phase 1 | COMPLETED | 48 | Aug 13, 2026 | ||||||
| ATTO-1310 Small moleculeCompletedNCT06787586 | Atopic Dermatitis (AD) | Phase 1 | COMPLETED | 108 | Jun 11, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALMR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Qiming Corporate GP VI, Ltd.10% Owner | Sell | -1,246 173,431 held | $29.00 | 10/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALMR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 5.5 % | 67.19 M | 2.48 M |
ALMR Institutional Ownership Trends
ALMR Short Interest
Shares sold short, counted twice a month.
7.85%
Short % of Float
of tradable shares sold short
2.8M
Shares Sold Short
+32.4% vs prior count
4.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
661.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALMR ranks across every disease it competes in
Competitive Position is a premium feature
See how ALMR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALMR News
ALMRAlamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Alamar Biosciences, Inc. will report its financial results for the third quarter of 2026 on November 3, 2026, after market close. A conference call will follow at 1:30 p.m. PT, which will be available for live streaming and later replay. The company emphasizes its role in Precision Proteomics, focusing on advanced protein detection technologies.
Read more →ALMR▼ -15.4%on this news· ran to -34% by day 3shared move
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Alamar Biosciences has appointed Bob Ragusa, former CEO of GRAIL, to its board of directors, enhancing its leadership team. Alongside Ragusa, John Brottem joins as general counsel and Amelia Merrill as Chief People Officer. The company aims to leverage its NULISA platform to improve disease detection capabilities.
Read more →ALMRLancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
Alamar Biosciences announced a study published in The Lancet Neurology, evaluating plasma biomarkers in Alzheimer's patients treated with lecanemab. The research highlights distinct biological responses during treatment, indicating that amyloid clearance and cognitive decline reflect different processes. The findings suggest that a comprehensive biomarker analysis is essential for understanding treatment effects.
Read more →ALMRAlamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Alamar Biosciences, Inc. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company's management will engage in a fireside chat, which will be accessible via a live and archived webcast. Alamar is recognized for its advanced proteomics technology aimed at early disease detection.
Read more →ALMRAlamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Alamar Biosciences has launched the NULISAseq Immune 340 Panel, a comprehensive multiplexed immune profiling tool that measures approximately 340 immune-related proteins from a single sample. This panel enhances the understanding of the immune proteome, aiding research in cancer, cardiovascular, metabolic diseases, and autoimmune conditions. The technology promises to improve biomarker discovery and therapeutic development.
Read more →ALMRALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
ALZpath has expanded its strategic agreement with Alamar Biosciences to include clinical diagnostics for Alzheimer's disease. Alamar now holds commercial rights to use ALZpath's pTau217 antibody in blood-based diagnostic tests. This collaboration aims to enhance the accessibility of effective Alzheimer's testing for clinicians and patients, aligning with recent trends in blood biomarker adoption.
Read more →ALMRAlamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
Alamar Biosciences, Inc. will report its second quarter 2026 financial results on August 10, 2026, after market close. A conference call will follow at 1:30 p.m. PT, accessible via webcast. The company focuses on Precision Proteomics, utilizing advanced technology for protein detection.
Read more →ALMRAlamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
Alamar Biosciences has partnered with leading universities to launch a national initiative aimed at advancing blood-based biomarkers for Alzheimer's disease and related conditions. The project will analyze approximately 21,000 plasma samples using the NULISAseq Neuro 220 panel, creating a publicly accessible dataset linked to existing Alzheimer’s research. This initiative aims to enhance biomarker discovery and facilitate AI-driven research in neurodegenerative diseases.
Read more →ALMR▲ +7.3%on this newsshared move
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
Alamar Biosciences announced that its NULISA platform will be highlighted in over 140 presentations at the Alzheimer's Association International Conference (AAIC) 2026. This significant increase in data showcases the growing acceptance of multiplex protein profiling in Alzheimer's research. The company will also host a workshop demonstrating new assays that enhance detection and staging of Alzheimer's disease.
Read more →ALMRAlamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
Alamar Biosciences has launched the first commercial eMTBR-Tau immunoassay, which provides a non-invasive blood-based measurement of tau tangle pathology associated with Alzheimer's disease. This assay is part of the NULISAseq Neuro 220 panel and is designed to enhance disease staging and therapeutic response monitoring. Alamar will present data on this innovation at the AAIC 2026 workshop.
Read more →ALMRAlamar Biosciences Reports First Quarter 2026 Financial Results
Alamar Biosciences reported a record revenue of $26 million for Q1 2026, marking a 99% increase from the previous year. The company launched two new products aimed at neurodegenerative diseases and successfully completed an IPO, raising $220 million. However, operating and net losses also increased during this period.
Read more →ALMRAlamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
Alamar Biosciences, Inc. will participate in the BofA Securities 2026 Healthcare Conference in Las Vegas. The presentation is scheduled for May 12 at 3:40 p.m. PT. The company focuses on Precision Proteomics to improve disease detection through its proprietary technologies.
Read more →About Alamar Biosciences, Inc.
Headquarters47071 BAYSIDE PARKWAY, FREMONT, CA, 94538
Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next ALMR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime